Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 2019.

Autor: Merdrignac L; Epidemiology Department, Epiconcept, Paris, France. Electronic address: l.merdrignac@epiconcept.fr., Aït El Belghiti F; Direction des maladies infectieuses, Santé Publique France, Paris, France., Pandolfi E; Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy., Acosta L; Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; Departament d'Estadística i Investigació Operativa, Universitat Politècnica de Catalunya- BarcelonaTech (UPC), Barcelona, Spain., Fabiánová K; National Institute of Public Health, Prague, Czech Republic., Habington A; Children's Health Ireland, Crumlin, Dublin, Ireland., García Cenoz M; Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain., Bøås H; Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway., Toubiana J; Biodiversité et Epidémiologie des bactéries et pathogènes, Institut Pasteur, Paris, France; National Reference Center for Whooping Cough and Other Bordetella Infections, Institut Pasteur, Paris, France., Tozzi AE; Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy., Jordan I; Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain., Zavadilová J; National Institute of Public Health, Prague, Czech Republic., O'Sullivan N; Children's Health Ireland, Crumlin, Dublin, Ireland., Navascués A; Hospital Universitario Navarra, Pamplona., Flem E; Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway., Croci I; Preventive and Predictive Medicine Research Unit, Bambino Gesù Children's Hospital, IRCSS, Rome, Italy., Jané M; Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; University of Barcelona, Barcelona, Spain., Křížová P; National Institute of Public Health, Prague, Czech Republic., Cotter S; Health Protection Surveillance Centre, Dublin, Ireland., Fernandino L; Instituto de Salud Pública de Navarra, IdiSNA - Navarre Institute for Health Research, Pamplona, Spain., Bekkevold T; Division of Infection Control, Norwegian Institute of Public Health, P.O. Box 222, Skøyen, 0213 Oslo, Norway., Muñoz-Almagro C; Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Barcelona, Spain; Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain., Bacci S; European Centre for Diseases Control and Prevention, Stockholm, Sweden., Kramarz P; European Centre for Diseases Control and Prevention, Stockholm, Sweden., Kissling E; Epidemiology Department, Epiconcept, Paris, France., Savulescu C; Epidemiology Department, Epiconcept, Paris, France.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Apr 02; Vol. 42 (9), pp. 2370-2379. Date of Electronic Publication: 2024 Mar 11.
DOI: 10.1016/j.vaccine.2024.02.090
Abstrakt: Background: Monitoring effectiveness of pertussis vaccines is necessary to adapt vaccination strategies. PERTINENT, Pertussis in Infants European Network, is an active sentinel surveillance system implemented in 35 hospitals across six EU/EEA countries. We aim to measure pertussis vaccines effectiveness (VE) by dose against hospitalisation in infants aged <1 year.
Methods: From December 2015 to December 2019, participating hospitals recruited all infants with pertussis-like symptoms. Cases were vaccine-eligible infants testing positive for Bordetella pertussis by PCR or culture; controls were those testing negative to all Bordetella spp. For each vaccine dose, we defined an infant as vaccinated if she/he received the corresponding dose >14 days before symptoms. Unvaccinated were those who did not receive any dose. We calculated (one-stage model) pooled VE as 100*(1-odds ratio of vaccination) adjusted for country, onset date (in 3-month categories) and age-group (when sample allowed it).
Results: Of 1,393 infants eligible for vaccination, we included 259 cases and 746 controls. Median age was 16 weeks for cases and 19 weeks for controls (p < 0.001). Median birth weight and gestational age were 3,235 g and week 39 for cases, 3,113 g and week 39 for controls. Among cases, 119 (46 %) were vaccinated: 74 with one dose, 37 two doses, 8 three doses. Among controls, 469 (63 %) were vaccinated: 233 with one dose, 206 two doses, 30 three doses. Adjusted VE after at least one dose was 59 % (95 %CI: 36-73). Adjusted VE was 48 % (95 %CI: 5-71) for dose one (416 eligible infants) and 76 % (95 %CI: 43-90) for dose two (258 eligible infants). Only 42 infants were eligible for the third dose.
Conclusions: Our results suggest moderate one-dose and two-dose VE in infants. Larger sample size would allow more precise estimates for dose one, two and three.
Competing Interests: Declaration of competing interest No conflict of interest to declare except for Elmira Flem who has been employed since April 2019 by Merck & Co., Inc., North Wales, PA, USA. The work for the current study was conducted by Dr. Flem under the previous affiliation at the Norwegian Institute of Public Health.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: